




# Figures to know about the 2025 metastatic Breast Cancer database



## Selection criteria

- Female or male patients
- ≥18 years old
- with mBC whose first metastatic event was treated (completely or partially) in a French Comprehensive Cancer Center

**Selection period:** 2008-2023

**Database extracted** in 02/2025

## De novo / relapsed

**13 144**

patients with **de novo mBC**

**25 141**

patients with **relapsed mBC**

## Metastatic disease

*At mBC diagnosis*

**8 359** patients  
with 3 or more metastatic sites

**Visceral**  
16 700  
(44%)

**CNS**  
2 536  
(7%)

**Bone**  
10 156  
(27%)

**Other site**  
17 952  
(47%)


**38 285** patients with  
**metastatic breast cancer** (mBC)

♂ **313**      ♀ **37 972**

## HR / HER2 profiles

Global profile determined:

- within 3 months from mBC diagnosis or
- at primary tumor if not available at mBC diagnosis



## BRCA testing

**8 160** patients  
have undergone **BRCA testing**

► **707** patients with a **germline BRCA mutation**

## Follow-up

**Median follow-up 94,1** months  
*According to reverse Kaplan-Meier Method*

### Minimum estimated follow-up

- 36 months for 33 882 patients
- 60 months for 28 178 patients